Clinical Trials Browser

Terminated × olaparib × Endocrine × Clear all

NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 11 charts

EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma